SOMERSET, NJ—Catalent Pharma Solutions will invest $27 million to commercialize Zydis Ultra, an oral disintegrating tablet (ODT) coating that allows for an increased drug load and taste-masking when used with the company’s Zydis ODT dosage form. The coating enables the active ingredient dosage to be up to four times higher than in a conventional Zydis ODT while maintaining the speed of dispersion and superior mouth feel. More than 36 products have been launched using the Zydis platform in more than 60 countries. The coating expands the range of drug candidates that can be formulated using the company’s ODT platform, including analgesics, anti-allergy treatments. and anti-infectives.